Aldeyra reports reproxalap improves dry eye disease signs, symptoms - Healio

Reproxalap 0.25% ophthalmic solution achieved primary and secondary endpoints in a trial investigating treatment of dry eye disease, Aldeyra Therapeutics announced in a press release.In a double-masked, sequence-randomized, vehicle-controlled crossover clinic…

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.Back to Healio Reproxalap 0.25% ophthalmic solution ach… [+1444 chars]

full article...